Contrast Media Market Key Players and Global Forecast 2022

According to research report the global contrast media market is expected to reach USD 5.53 Billion by 2022 from an estimated USD 4.57 Billion in 2017, growing at a CAGR of 3.9% during the forecast period. Growth in the contrast media market can primarily be attributed to factors such as increasing number of approvals for contrast agents and growing number of public & private diagnostic centers. The increasing number of research and funding activities for research of contrast agents and their applications provides immense opportunities for players in the contrast media market

The key players in this market are continuously striving to gain product approvals to secure larger shares and expand their existing product portfolios. The overall market was dominated by Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A (Italy), Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), and Subhra Pharma Private Limited (India).

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911

Bayer HealthCare (Germany) was the leading player in the contrast media/contrast agents market with a share of ~24% in 2015. The company continuously strives to strengthen its market position in various geographies by focusing on getting approvals for contrast media products across the world. Gadovist injection, a gadolinium-based contrast agent by Bayer, has received FDA approval in the U.S. and Japan. Gadovist is the first FDA-approved contrast agent for pediatric patients less than 2 years of age, including term neonates. The company’s major share in the market can be attributed to its broad product portfolio, several years of experience, extensive distribution channel, and various growth strategies, such as product approvals, collaborations, and expansions. The company focuses on developing innovative healthcare products with a positive cost-benefit ratio.

Bayer HealthCare invested 5.8%, 5.5%, and 5.5% of its total healthcare revenue in 2013, 2014, and 2015, respectively, in R&D activities. The company has gained a major share in the contrast media/contrast agents market on account of its comprehensive product portfolio, wide geographical reach; focus on organic growth strategies, as well as constant focus on research and developmental activities.

GE Healthcare (U.S.) held the second-largest share of ~21% in the contrast media/contrast agents market in 2015. The firm has a strong customer base in approximately 175 countries, primarily operating in North America, Europe, the Pacific Basin, the Americas, and the Middle East & Africa. Some subsidiaries of the firm include GE Healthcare USA Holdings, Inc., GE Healthcare Ltd. (Japan), GE Healthcare Biosciences AB (U.S.), and GE Healthcare AS (Norway). GE Healthcare received the Norwegian Medicines Agencys (NOMA) approval for SONAZOID, a contrast agent used in ultrasound imaging of focal liver lesions. However, with competition in the market and the entry of new companies, it is necessary for GE to innovate continuously in order to keep its technology at the forefront and maintain its position in the market. The company’s robust product portfolio, large number of subsidiaries, focus on customers, and new product launches have also helped expand its share in the contrast media/contrast agents market.

Sample of the report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=911

Players operating in the contrast media/contrast agents market adopted strategies such as product approvals, which was the most-preferred strategy (43.6% of the total strategic developments in the market during 2013 to 2016). The key players that have adopted this strategy include Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A (Italy), Spago Nanomedicine AB (Sweden), and CMC Contrast AB (Sweden).

Clinical Microbiology Market Future Growth Forecast to 2022

According to research report Clinical Microbiology Market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018, at a CAGR of 6.4%.

The major factors driving the growth of the clinical microbiology market include technological advancements in the field of infectious disease diagnostics, rising incidence and prevalence of infectious diseases and growing outbreak of epidemics, and the increased funding and public-private investments for the development of novel products for infectious disease diagnosis.

Pharmaceutical applications are expected to dominate the microbiology testing market in 2018

The microbiology testing market is segmented on the basis of applications into pharmaceutical, clinical, food testing, energy, chemical and material manufacturing, and environmental applications. The pharmaceutical applications segment is expected to dominate the overall microbial testing market in 2018 due to the presence of well-established and globally accepted regulations that govern the evaluation of microbial contamination during pharmaceutical manufacturing and raw material sourcing processes.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=219135367

Laboratory instruments are projected to hold the largest share of the clinical microbiology instruments market in 2018

The clinical microbiology market is segmented on the basis of products into instruments (laboratory instruments and microbiology analyzers) and reagents (pathogen-specific kits and general reagents). The laboratory instruments products segment is expected to command the largest share of the global clinical microbiology instruments market in 2018 due to factors such as continuous technological advancements in the field of microbiology testing instruments and the focus on laboratory automation (coupled with the integration of robotics with conventional microbiology instruments).

Respiratory diseases are expected to be the largest diseases area in clinical microbiology market in 2018

On the basis of disease area, the clinical microbiology market is segmented into respiratory diseases, bloodstream infections (BSIs), gastrointestinal (GI) diseases, sexually transmitted diseases (STDs), urinary tract infections (UTIs), periodontal diseases, and other diseases (including cardiovascular disease, central nervous system infections, connective tissue & joint diseases, and skin diseases). The respiratory disease segment is estimated to account for largest share of the global clinical microbiology market owing to the large patient population suffering from respiratory diseases, rising prevalence of target respiratory diseases (including TB, asthma, COPD, and bronchitis) across developing countries, and increasing number of epidemic outbreaks of respiratory infections.

North America is expected to dominate the clinical microbiology market in 2018

Geographically, the market is segmented into North America (the US and Canada), Europe (Germany, the UK, France, and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of APAC), and the Rest of the World (Latin America, and the Middle East and Africa). North America is expected to account for the largest share of the global clinical microbiology market in 2018 due to easy accessibility and high adoption of advanced diagnostic techniques, technological advancements in microbial testing techniques, rising geriatric population, and growing public-private funding to support microbiology-based research in the region.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=219135367

The major players operating in the microbiology testing/clinical microbiology market include bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US), Hologic, Inc. (US), QIAGEN N.V. (The Netherlands), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Shimadzu Corporation (Japan), 3M Company (US), and Neogen Corporation (US), among others.

Liquid Biopsy Market by Cancer Type and Product Global Forecast 2022

According to research report the global liquid biopsy market is projected to reach USD 2,047.9 million by 2022

According to research report the global liquid biopsy market is projected to reach USD 2,047.9 million by 2022 from USD 715.7 million in 2017, at a CAGR of 23.4%. The factors driving the growth of this market are the increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.
Speak to analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=13966350 
Cancers in areas such as the bones, brain, pancreas, or other organs were hard to access with liquid biopsy. However, post 2014, the sensitivity of liquid biopsy tests has improved greatly. Presently, ultra-sensitive methods such as digital PCR, NGS, and microfluidics are designed to capture CTCs and ctDNA—key biomarkers for cancer. These methods permit the analysis of ctDNA, providing physicians with important biomarker information to take effective therapeutic decisions in almost all cancer areas. The development of technologically advanced liquid biopsy products is aiding the growth of the market.
In this report, the market is segmented on the basis of product, circulating biomarker, clinical application, application, end user, and region. On the basis of product, the global liquid biopsy market is segmented into assays kits, instruments, and services. The assay kits segment is expected to account for the largest share in the liquid biopsy market in 2017. Increase in demand for liquid biopsy tests, increasing basic research and commercial applications of liquid biopsy, and the need for reliable and specific assays are expected to drive the liquid biopsy assay kits market. It is also the fastest-growing segment in the products market during the forecast period.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 
Based on circulating biomarkers the market is categorised into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The extracellular vesicles is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in EV research from biofluids such as the blood and urine of cancer patients as a means of disease diagnosis and therapeutic monitoring. 
Based on clinical application, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The early cancer screening segment is expected to be the fastest-growing segment in the clinical application market during the forecast period. The factor driving the growth of this segment is the ability to detect populations at high risk of cancer using liquid biopsy during early stages of cancer through early screening methods. 
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which includes reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the application market during the forecast period. This is due to growing NIPT applications in gender identification, identification of trisomies, and other genetic abnormalities which include monosomy X and microdeletions. NIPT is also replacing amniocentesis in high-risk pregnancies.
Based on end user, the liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the fastest-growing end-user segment of the liquid biopsy market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories. 
Geographically, the liquid biopsy market in the APAC region is expected to register the highest CAGR during the forecast period. Rising disposable incomes in the middle-class populations have led to an increase in healthcare spending in India and China. This, along with infrastructural developments and rising penetration of cutting-edge diagnostic technologies in these countries, is a major factor providing significant growth opportunities for manufacturers and distributors of liquid biopsy products in this region.
 

Surgical Microscopes Market - 7 Countries offers significant growth opportunities in the market

According to research report the global surgical microscopes market is projected to reach USD 915.6 million by 2021 from USD 508.1 million in 2016, growing at a CAGR of 12.5% during the forecast period.

The global surgical/operating microscopes market is segmented on the basis of application, end user, and region. On the basis of application, the market is broadly segmented into neuro and spine surgery, plastic and reconstructive surgery, ophthalmology, gynecology and urology, oncology, dentistry, ENT surgery, and documentation. In 2016, the neuro and spine surgery segment is expected to account for the largest share of the market due to the increasing demand for surgical/operating microscopes in neurosurgery. However, the oncology segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the increasing prevalence of cancer around the world.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=179225920

On the basis of end user, the surgical/operating microscopes market is segmented into hospitals and outpatient facilities. In 2016, hospitals are estimated to account for the largest share of the global surgical/operating microscopes market. The growing usage of surgical/operating microscopes in complex neurology, ENT, and dental procedures, and implementation of less-invasive surgical instruments during MIS procedures in hospitals are key market drivers in this end-user segment.

In 2016, North America is expected to account for the largest share of the global surgical/operating microscopes market. Factors such as the growing demand for minimally invasive surgical procedures, infrastructural advancements in healthcare facilities, and increase in the number of surgeries are driving the growth of the North American surgical/operating microscopes market.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=179225920

The Asia-Pacific region (comprising China, India, and RoAPAC) is expected to grow at the highest CAGR during the forecast period. The high growth in this regional segment can primarily be attributed to the presence of high-growth markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore. In recent years, the Asia-Pacific market for surgical/operating microscopes has witnessed significant growth due to improving R&D infrastructure, rising focus of market players, and increasing government initiatives.

Wearable Medical Device Market Top Players and Business Insights

According to research report the wearable medical devices market is expected to reach USD 14.41 Billion by 2022 from USD 5.31 Billion in 2016, at a CAGR of 18.3% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.
The key growth strategies adopted by the top companies (profiled in the report) include partnerships, collaborations, and agreements; new product launches and approvals; expansion, and acquisition.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=81753973
Prominent players in the wearable medical device market include Fitbit Inc. (U.S.), Philips Healthcare (Netherlands), Garmin Ltd. (Switzerland), LifeWatch AG. (Switzerland), Omron Corporation (Japan), Drägerwerk AG & Co. KGaA (U.S.), Withings SA.(France), Jawbone Inc. (U.S.) and Polar Electro Oy (Finland).
Companies are focused on various organic and inorganic growth strategies such as collaborations, and agreements; new product launches and approvals; expansion, and acquisition. These strategies helped the market players to build a robust position in the market, which helped in increasing demand of customers, and to expand their presence in the global market.
This research study involves the use of extensive secondary sources; directories; databases such as Hoovers, Bloomberg Business, Factiva, and Avention; white papers; annual reports; company house documents; and SEC filings of companies.
For estimating the size of the wearable medical device market, the segmental market revenues were obtained from secondary sources through extensive primary interviews. The segment-level markets were then added up to reach the total market size of each segment (type, distribution channel, End use, and applications). The wearable medical device market size was derived by adding the markets of all these segments. The total market derived through the bottom-up approach was again validated through secondary sources and interviews.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973
The overall market size derived by the bottom-up approach was used in the top-down procedure to estimate the size of the wearable medical device market through the percentage splits obtained from secondary and primary research for each product segment

Medical Holography Market Top Players and growth Strategies

According to research report the medical holography market is expected to grow from USD 163.4 million in 2015 to USD 953.9 million by 2021, at a CAGR of 33.7% from 2016 to 2021. The global medical holography market is in nascent stage with some of its products are still in developing stage. The global medical holography displays, software, and prints market is dominated by Holoxica Ltd. (U.K.), Zebra Imaging (U.S.), Echopixel (U.S.); while, the global medical holography microscopes market is dominated by Ovizio Imaging systems (Belgium), Lyncee Tec (Switzerland), and Phase Holographic Imaging (Sweden). In addition to these players, Realview Imaging (Israel), a prominent company in medical holography market is ready to launch advanced holography products for interventional and diagnostic imaging in the market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=183930222

RealView Imaging Ltd. (Israel) is a leading player in medical holography market, has developed the holographic clinical beta system, a system to project real-time medical holograms. The company is focused on finalizing the designing and production of its first commercial holographic technology integrated product and is dedicated towards raising funds to cater to its R&D activities. Holoxica Ltd. (U.K.) is another leading player in this market and is specialist in making full-color 3D holograms and holographic displays for scientific and medical applications. The company has developed hologram images of human brain, liver, eye, and ear to help doctors during surgeries.

On the other side Zebra Imaging Inc. (U.S.), a leading provider of three-dimensional (3D) digital holographic images and interactive 3D displays, is focusing on partnerships and collaboration to strengthen its presence in the market.

Focusing on digital holography microscopy, Lyncee Tec SA (Switzerland) and Ovizio Imaging systems (Belgium) are offering of holography microscopes for various biomedical research applications. Both these companies are laying emphasis on launching advanced microscopes by collaborating with other research organizations and academic universities.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=183930222

Industry players adopted the strategy of new product launches; mergers and acquisitions; expansions; investments; agreements, collaborations, and partnerships as major growth strategies to achieve growth in the global medical holography market. In order to strengthen their market position and customer base, companies adopted agreements, partnerships, and collaborations as a key growth strategy. This strategy also helped companies to garner larger market shares and strengthen their customer base and production capacities. For instance, in June 2016, zSpace partnered with Visible Body (U.S.) to offer new software for zSpace’s VR (virtual reality) solution to provide virtual 3D human anatomic models of the human body to healthcare professionals, patients, and students across the globe.

Refurbished Medical Devices Market - Opportunities for Market Leaders in the Near Future

According to research report Refurbished Medical Devices Market - [Ultrasound, MRI, CT Scanner, C-Arm, Nuclear Imaging Systems, Heart-Lung Machine, Surgical, CO2 Monitor, Patient monitor, Pulse Oximeter, AED Defibrillator, Cath labs, Strechers, Endoscopy] - Global Forecast to 2021 is expected to reach USD 11.91 Billion by 2021 from USD 6.55 Billion in 2016, at a CAGR of 12.7%

Refurbishing of medical devices refers to restoring used equipment or systems into a condition of safety and effectiveness comparable to new ones through repairs, rework, updates, and replacement of worn parts.

The global Refurbished Medical Devices Market is poised to grow at a CAGR of 12.5% in the forecast period. This market is divided into four major regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2014, North America is expected to account for the largest share of the global Refurbished Medical Devices Market, followed by Europe. The large market share of this market is attributed to the growing aging population, high incidence/prevalence of various diseases (such as cancer and CVD), favorable regulatory scenario for sale and use of refurbished medical systems in both the U.S. and Canada, and declining insurance reimbursements for imaging procedures.
Get sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=770
However, the Asia-Pacific region is poised to grow at the highest CAGR of 13.7% during the forecast period. This is primarily due to the privatization of the healthcare sector, poor reimbursement scenario, huge patient population base, and presence of a large number of low budgets hospitals/clinics.
A number of players in the Refurbished Medical Devices Market are striving to expand their presence in both mature and emerging markets. For instance, in March 2010, the company launched its CT system manufacturing facility in Bangalore, India. Under this facility, the company refurbishes used medical devices. This enhanced the company’s refurbished medical equipment business in the emerging Indian market. Likewise, in November 2014, Royal Philips launched a new healthcare imaging system refurbishment facility in Best, the Netherlands. This enabled the company to offer a wide range of refurbished imaging devices in Europe.
Several companies such as Philips Healthcare (Netherlands), Soma Technology, Inc. (U.S.), GE Healthcare (U.K.), Block Imaging International, Inc. (U.S.), Siemens Healthcare (Germany), and DRE, Inc. (U.S.) are investing in this high-growth market to gain higher profits and to increase their shares in the global Refurbished Medical Devices Market.